CN105367551A - Dabigatran etexilate glycolate, preparation method and applications thereof - Google Patents
Dabigatran etexilate glycolate, preparation method and applications thereof Download PDFInfo
- Publication number
- CN105367551A CN105367551A CN201410408463.1A CN201410408463A CN105367551A CN 105367551 A CN105367551 A CN 105367551A CN 201410408463 A CN201410408463 A CN 201410408463A CN 105367551 A CN105367551 A CN 105367551A
- Authority
- CN
- China
- Prior art keywords
- glycollate
- dabigatran etcxilate
- solvate
- hydrate
- dabigatran
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 33
- KSGXQBZTULBEEQ-UHFFFAOYSA-N dabigatran etexilate Chemical compound C1=CC(C(N)=NC(=O)OCCCCCC)=CC=C1NCC1=NC2=CC(C(=O)N(CCC(=O)OCC)C=3N=CC=CC=3)=CC=C2N1C KSGXQBZTULBEEQ-UHFFFAOYSA-N 0.000 title abstract description 9
- 229960000288 dabigatran etexilate Drugs 0.000 title abstract description 6
- AEMRFAOFKBGASW-UHFFFAOYSA-M Glycolate Chemical compound OCC([O-])=O AEMRFAOFKBGASW-UHFFFAOYSA-M 0.000 title abstract 4
- 239000012453 solvate Substances 0.000 claims abstract description 55
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 25
- 239000003814 drug Substances 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 10
- 208000024172 Cardiovascular disease Diseases 0.000 claims abstract description 3
- 230000002265 prevention Effects 0.000 claims abstract description 3
- 229960003850 dabigatran Drugs 0.000 claims description 173
- YBSJFWOBGCMAKL-UHFFFAOYSA-N dabigatran Chemical compound N=1C2=CC(C(=O)N(CCC(O)=O)C=3N=CC=CC=3)=CC=C2N(C)C=1CNC1=CC=C(C(N)=N)C=C1 YBSJFWOBGCMAKL-UHFFFAOYSA-N 0.000 claims description 172
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 claims description 28
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 26
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 21
- 239000000463 material Substances 0.000 claims description 20
- 239000002904 solvent Substances 0.000 claims description 19
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims description 16
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 16
- 238000001035 drying Methods 0.000 claims description 16
- 239000002253 acid Substances 0.000 claims description 14
- 239000003960 organic solvent Substances 0.000 claims description 14
- 150000001875 compounds Chemical class 0.000 claims description 13
- 238000002425 crystallisation Methods 0.000 claims description 13
- 230000008025 crystallization Effects 0.000 claims description 13
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 13
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 12
- 239000003795 chemical substances by application Substances 0.000 claims description 9
- 239000003826 tablet Substances 0.000 claims description 9
- 238000001953 recrystallisation Methods 0.000 claims description 7
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 6
- 239000008187 granular material Substances 0.000 claims description 6
- ZWEHNKRNPOVVGH-UHFFFAOYSA-N 2-Butanone Chemical compound CCC(C)=O ZWEHNKRNPOVVGH-UHFFFAOYSA-N 0.000 claims description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 4
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 3
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 3
- 229960001701 chloroform Drugs 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- DURPTKYDGMDSBL-UHFFFAOYSA-N 1-butoxybutane Chemical compound CCCCOCCCC DURPTKYDGMDSBL-UHFFFAOYSA-N 0.000 claims description 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims description 2
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 2
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical group CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 claims description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 2
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 claims description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical class CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 2
- 206010047249 Venous thrombosis Diseases 0.000 claims description 2
- 229940043232 butyl acetate Drugs 0.000 claims description 2
- 229940093499 ethyl acetate Drugs 0.000 claims description 2
- 238000001914 filtration Methods 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- 239000007902 hard capsule Substances 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- JMMWKPVZQRWMSS-UHFFFAOYSA-N isopropanol acetate Natural products CC(C)OC(C)=O JMMWKPVZQRWMSS-UHFFFAOYSA-N 0.000 claims description 2
- 229940011051 isopropyl acetate Drugs 0.000 claims description 2
- GWYFCOCPABKNJV-UHFFFAOYSA-N isovaleric acid Chemical compound CC(C)CC(O)=O GWYFCOCPABKNJV-UHFFFAOYSA-N 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- XNLICIUVMPYHGG-UHFFFAOYSA-N pentan-2-one Chemical compound CCCC(C)=O XNLICIUVMPYHGG-UHFFFAOYSA-N 0.000 claims description 2
- 238000010992 reflux Methods 0.000 claims description 2
- 239000007901 soft capsule Substances 0.000 claims description 2
- 238000005406 washing Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 8
- 229940079593 drug Drugs 0.000 abstract description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 32
- 239000000203 mixture Substances 0.000 description 19
- 241001465754 Metazoa Species 0.000 description 18
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 description 17
- 241000700159 Rattus Species 0.000 description 12
- 239000013543 active substance Substances 0.000 description 10
- -1 benzimidazoles compound Chemical class 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000007689 inspection Methods 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 239000000843 powder Substances 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 7
- 238000001802 infusion Methods 0.000 description 7
- 239000007924 injection Substances 0.000 description 7
- 238000002347 injection Methods 0.000 description 7
- 231100000419 toxicity Toxicity 0.000 description 7
- 230000001988 toxicity Effects 0.000 description 7
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 239000007787 solid Substances 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 5
- 230000015271 coagulation Effects 0.000 description 5
- 238000005345 coagulation Methods 0.000 description 5
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 5
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 5
- 239000008101 lactose Substances 0.000 description 5
- 210000000056 organ Anatomy 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000010998 test method Methods 0.000 description 5
- 231100000331 toxic Toxicity 0.000 description 5
- 230000002588 toxic effect Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 4
- 230000000052 comparative effect Effects 0.000 description 4
- 239000002552 dosage form Substances 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 239000000543 intermediate Substances 0.000 description 4
- 231100001252 long-term toxicity Toxicity 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000008108 microcrystalline cellulose Substances 0.000 description 4
- 229940016286 microcrystalline cellulose Drugs 0.000 description 4
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 4
- 238000004806 packaging method and process Methods 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 238000005160 1H NMR spectroscopy Methods 0.000 description 3
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 3
- 229940123900 Direct thrombin inhibitor Drugs 0.000 description 3
- 206010013786 Dry skin Diseases 0.000 description 3
- 229930195725 Mannitol Natural products 0.000 description 3
- 229920000881 Modified starch Polymers 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 231100000403 acute toxicity Toxicity 0.000 description 3
- 230000007059 acute toxicity Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 208000034158 bleeding Diseases 0.000 description 3
- 230000000740 bleeding effect Effects 0.000 description 3
- 230000023555 blood coagulation Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010835 comparative analysis Methods 0.000 description 3
- 229960004132 diethyl ether Drugs 0.000 description 3
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 3
- 229960003943 hypromellose Drugs 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000594 mannitol Substances 0.000 description 3
- 235000010355 mannitol Nutrition 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 231100000252 nontoxic Toxicity 0.000 description 3
- 230000003000 nontoxic effect Effects 0.000 description 3
- 229940066336 pradaxa Drugs 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011122 softwood Substances 0.000 description 3
- 239000003868 thrombin inhibitor Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 108010011485 Aspartame Proteins 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 206010033625 Pancreatic haemorrhage Diseases 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 description 2
- 208000007271 Substance Withdrawal Syndrome Diseases 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000215 acute (single dose) toxicity testing Toxicity 0.000 description 2
- 238000011047 acute toxicity test Methods 0.000 description 2
- 239000003708 ampul Substances 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 229940127219 anticoagulant drug Drugs 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 239000000605 aspartame Substances 0.000 description 2
- 235000010357 aspartame Nutrition 0.000 description 2
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 2
- 229960003438 aspartame Drugs 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 238000001354 calcination Methods 0.000 description 2
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 2
- 239000007910 chewable tablet Substances 0.000 description 2
- 229940068682 chewable tablet Drugs 0.000 description 2
- 239000013078 crystal Substances 0.000 description 2
- 230000007547 defect Effects 0.000 description 2
- 229960000935 dehydrated alcohol Drugs 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 239000007919 dispersible tablet Substances 0.000 description 2
- 239000002662 enteric coated tablet Substances 0.000 description 2
- 229960004756 ethanol Drugs 0.000 description 2
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 238000005286 illumination Methods 0.000 description 2
- YDTFRJLNMPSCFM-YDALLXLXSA-M levothyroxine sodium anhydrous Chemical compound [Na+].IC1=CC(C[C@H](N)C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 YDTFRJLNMPSCFM-YDALLXLXSA-M 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 229940100688 oral solution Drugs 0.000 description 2
- 239000006191 orally-disintegrating tablet Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 239000000049 pigment Substances 0.000 description 2
- 229940023488 pill Drugs 0.000 description 2
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
- 229920000053 polysorbate 80 Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 229960005080 warfarin Drugs 0.000 description 2
- PJVWKTKQMONHTI-UHFFFAOYSA-N warfarin Chemical compound OC=1C2=CC=CC=C2OC(=O)C=1C(CC(=O)C)C1=CC=CC=C1 PJVWKTKQMONHTI-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 238000005491 wire drawing Methods 0.000 description 2
- MEIRRNXMZYDVDW-MQQKCMAXSA-N (2E,4E)-2,4-hexadien-1-ol Chemical compound C\C=C\C=C\CO MEIRRNXMZYDVDW-MQQKCMAXSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 239000004254 Ammonium phosphate Substances 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005189 Embolism Diseases 0.000 description 1
- 235000016623 Fragaria vesca Nutrition 0.000 description 1
- 240000009088 Fragaria x ananassa Species 0.000 description 1
- 235000011363 Fragaria x ananassa Nutrition 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920002907 Guar gum Polymers 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012449 Kunming mouse Methods 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- MHQJUHSHQGQVTM-HNENSFHCSA-N Octadecyl fumarate Chemical compound CCCCCCCCCCCCCCCCCCOC(=O)\C=C/C(O)=O MHQJUHSHQGQVTM-HNENSFHCSA-N 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 239000004902 Softening Agent Substances 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- DOOTYTYQINUNNV-UHFFFAOYSA-N Triethyl citrate Chemical compound CCOC(=O)CC(O)(C(=O)OCC)CC(=O)OCC DOOTYTYQINUNNV-UHFFFAOYSA-N 0.000 description 1
- 238000002441 X-ray diffraction Methods 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000008351 acetate buffer Substances 0.000 description 1
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 150000008431 aliphatic amides Chemical group 0.000 description 1
- 229910000148 ammonium phosphate Inorganic materials 0.000 description 1
- 235000019289 ammonium phosphates Nutrition 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 230000002567 autonomic effect Effects 0.000 description 1
- 238000011888 autopsy Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000010241 blood sampling Methods 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- JHECKPXUCKQCSH-UHFFFAOYSA-J calcium;disodium;2-[2-[bis(carboxylatomethyl)amino]ethyl-(carboxylatomethyl)amino]acetate;hydrate Chemical compound O.[Na+].[Na+].[Ca+2].[O-]C(=O)CN(CC([O-])=O)CCN(CC([O-])=O)CC([O-])=O JHECKPXUCKQCSH-UHFFFAOYSA-J 0.000 description 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 description 1
- 206010061592 cardiac fibrillation Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 238000011284 combination treatment Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 229960001681 croscarmellose sodium Drugs 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 150000004691 decahydrates Chemical class 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- MNNHAPBLZZVQHP-UHFFFAOYSA-N diammonium hydrogen phosphate Chemical group [NH4+].[NH4+].OP([O-])([O-])=O MNNHAPBLZZVQHP-UHFFFAOYSA-N 0.000 description 1
- 150000004683 dihydrates Chemical class 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 230000002600 fibrillogenic effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 238000005469 granulation Methods 0.000 description 1
- 230000003179 granulation Effects 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 239000000665 guar gum Substances 0.000 description 1
- 235000010417 guar gum Nutrition 0.000 description 1
- 229960002154 guar gum Drugs 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 150000004688 heptahydrates Chemical class 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- 125000003707 hexyloxy group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])O* 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 1
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N iron oxide Inorganic materials [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 1
- 239000007791 liquid phase Substances 0.000 description 1
- 229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000007923 nasal drop Substances 0.000 description 1
- 229940100662 nasal drops Drugs 0.000 description 1
- 150000004690 nonahydrates Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- NDLPOXTZKUMGOV-UHFFFAOYSA-N oxo(oxoferriooxy)iron hydrate Chemical compound O.O=[Fe]O[Fe]=O NDLPOXTZKUMGOV-UHFFFAOYSA-N 0.000 description 1
- 208000021090 palsy Diseases 0.000 description 1
- 150000004686 pentahydrates Chemical class 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 239000002953 phosphate buffered saline Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000001253 polyvinylpolypyrrolidone Substances 0.000 description 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
- 231100000683 possible toxicity Toxicity 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 238000007493 shaping process Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 238000013112 stability test Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 229940071138 stearyl fumarate Drugs 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 235000019640 taste Nutrition 0.000 description 1
- 150000004685 tetrahydrates Chemical class 0.000 description 1
- 210000001541 thymus gland Anatomy 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001069 triethyl citrate Substances 0.000 description 1
- VMYFZRTXGLUXMZ-UHFFFAOYSA-N triethyl citrate Natural products CCOC(=O)C(O)(C(=O)OCC)C(=O)OCC VMYFZRTXGLUXMZ-UHFFFAOYSA-N 0.000 description 1
- 235000013769 triethyl citrate Nutrition 0.000 description 1
- 150000004684 trihydrates Chemical class 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001835 viscera Anatomy 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000020985 whole grains Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention provides a dabigatran etexilate glycolate represented by a general formula (I), a hydrate and/or a solvate thereof, wherein n is 1, 2 or 3. The present invention further provides a preparation method of the dabigatran etexilate glycolate, the hydrate and/or the solvate thereof, and applications in preparation of drugs for treatment or prevention of cardiovascular diseases. The dabigatran etexilate glycolate of the present invention has characteristics of good stability, high water solubility, high bioavailability, and low toxic-side effect. The formula (I) is defined in the specification.
Description
Technical field
The present invention relates to a kind of acid salt of dabigatran etcxilate, be specifically related to a kind of dabigatran etcxilate glycollate and its preparation method and application.
Background technology
Dabigatran (Dabigatran) is a kind of anti-coagulant of innovation, and namely thin blood medicine of new generation, on pharmacosystematics, belongs to " direct thrombin inhibitor " (DirectThrombinInhibitors, DTI).Current medical circle has studied the effect that confirmation " dabigatran " plays in multinomial clinical indication, and it likely replaces " warfarin " (warfarin) belonging to old-fashioned thin blood medicine, becomes in most of case for anticoagulant choice drug.
" dabigatran " enters human body with the form oral administration of its premedicant " dabigatran etcxilate " (dabigatranetexilate)." dabigatran etcxilate " is researched and developed by German BoehringerIngelheim, and in 2008 in Europe listing, commodity are called " Pradaxa ", and Canadian commodity are called " Pradax ".The Hong Kong Chinese commodity of " Pradaxa " are then called " hundred reach life ", and the Chinese trade name in China's Mainland and Taiwan is just in application examination & verification.At present, it is ratified with " Pradaxa " for trade(brand)name list marketing in existing 75 countries and regions.FDA (Food and Drug Adminstration) (FDA) ratifies by dabigatran etcxilate (a kind of oral direct thrombin inhibitor) for non-valve artrial fibrillation patient (AF) on September 20th, 2010, to reduce the risk that palsy and Systemic Vascular embolism occur for it.
Dabigatran etcxilate (DABIGATRANETEXILATE) is a kind of benzimidazoles compound of replacement, chemical name 3-[[[2-[[[4-[[[(hexyloxy) carbonyl] is amino] formamino] phenyl] is amino] methyl]-1-methyl isophthalic acid H-benzoglyoxaline-5-base] carbonyl] (pyridine-2-base) is amino] ethyl propionate, its molecular structural formula is as follows:
Molecular formula: C
34h
41n
7o
5, molecular weight: 627.74.
The solubleness of dabigatran etcxilate in water is less, and in the impact of pharmaceutical excipient with under preventing, it is not easy to stripping in pharmaceutical preparation, and the preparation of pharmaceutical preparation is subject to many limitations.In addition, the dabigatran etcxilate mesylate (referring to Chinese patent CN1675193A) gone on the market has the defects such as less stable, bioavailability is low, toxic side effect is large, therefore need to find the compound being more suitable for medicinal dabigatran etcxilate, to meet the demand of market and relative disease preventing and controlling.
Summary of the invention
Therefore, the object of the invention is to overcome the poor stability of dabigatran etcxilate and existing compound thereof, the defect such as bioavailability is low, toxic side effect is large, the dabigatran etcxilate glycollate of better, water-soluble larger, the more high and low toxic side effect of bioavailability of a kind of stability and hydrate thereof and/or solvate are provided, and their preparation method and application.
Term as used herein " solvate ", refers to the crystallized form comprising one or more organic solvent molecule in periodic three-dimensional arrangement.
Phrase used herein " pharmaceutically acceptable ", refers in the scope that judges in rational medicine and is applicable to not have with the contact tissue of the mankind or animal excessive toxicity, pungency, anaphylaxis or other problem or complication and the compound with rational benefit/risk ratio, material, composition and/or formulation simultaneously.
The invention provides the following dabigatran etcxilate glycollate of a kind of general formula, its hydrate and/or solvate:
Wherein, n is 1,2 or 3.
According to dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, wherein, the water of 0.5 ~ 10 molecule in the hydrate of dabigatran etcxilate glycollate described in per molecule, can be contained, preferably can contain the water of 0.5 ~ 2 molecule.The solvent of 0.5 ~ 10 molecule can be contained in the solvate of dabigatran etcxilate glycollate described in per molecule, preferably can contain the solvent of 0.5 ~ 2 molecule.
Such as, the hydrate of dabigatran etcxilate glycollate of the present invention can be semihydrate, monohydrate, sesqui hydrate, dihydrate, two times of semihydrates, trihydrate, three times of semihydrates, tetrahydrate, four times of semihydrates, pentahydrate, five times of semihydrates, hexahydrate, six times of semihydrates, heptahydrate, seven times of semihydrates, eight hydrates, octuple semihydrate, nonahydrate, nine times of semihydrates or decahydrates.Again such as, the solvate of the dabigatran etcxilate glycollate of per molecule can contain the solvent of half molecule, 1 molecule, 1.5 molecules, 2 molecules, 2.5 molecules, 3 molecules, 3.5 molecules, 4 molecules, 4.5 molecules, 5 molecules, 5.5 molecules, 6 molecules, 6.5 molecules, 7 molecules, 7.5 molecules, 8 molecules, 8.5 molecules, 9 molecules, 9.5 molecules or 10 molecules.
Should illustrate, the hydrate of the above-mentioned dabigatran etcxilate glycollate of the present invention enumerated or solvate, mainly a kind of existence form of producing in crystallization or purge process of dabigatran etcxilate glycollate of the present invention, crystal water contained by it or crystallization organic solvent normally can control or remove, such as, crystal water or crystallization organic solvent can be removed by mode such as heating calcination or calcining etc.Therefore, the hydrate of dabigatran etcxilate glycollate of the present invention and solvate still belong to the content of technical scheme content of the present invention and scope of patent protection.
According to dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, wherein, described solvate can be one or more in alcohol solvent compound, Methanol Solvate, acetone solvate, acetonitrile solvate, ethyl acetate solvate, tetrahydrofuran solvate and ether solvent compound.
According to dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, wherein, in described hydrate, dabigatran etcxilate glycollate can account for more than 95wt%, can be preferably more than 98wt%, can be more preferably more than 99wt%.In described solvate, dabigatran etcxilate glycollate can account for more than 95wt%, can be preferably more than 98wt%, can be more preferably more than 99wt%.
Present invention also offers the method for preparation dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, the method can comprise: dabigatran etcxilate and oxyacetic acid are mixed salify and crystallization in water or the first organic solvent, after filtration, after washing, drying, water or the second organic solvent is used to carry out recrystallization, obtained described dabigatran etcxilate glycollate, its hydrate or solvate.Those skilled in the art as required, by conventional means, can remove partial solvent etc., to accelerate the formation of crystallization as reduced Tc or steaming.
According to method of the present invention, wherein, the step of described mixing salify can be carried out under 0 DEG C of reflux temperature to water or the first organic solvent, can preferably carry out at 0 ~ 30 DEG C.As preferably, the step of described crystallization can room temperature or lower than the condition of room temperature under carry out, can preferably carry out at 0 ~ 20 DEG C.Described first organic solvent and the second organic solvent identical or different, ethanol, methyl alcohol, propyl alcohol, Virahol, butanols, ethyl formate, ethyl acetate, isopropyl acetate, butylacetate, ether, isopropyl ether, n-butyl ether, glycol dimethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), sherwood oil, acetonitrile, methylene dichloride, trichloromethane, normal hexane, hexanaphthene, acetone, butanone, pentanone, toluene, N,N-DIMETHYLACETAMIDE or dimethylbenzene can be selected from.
According to method of the present invention, wherein, the mol ratio of described dabigatran etcxilate and described oxyacetic acid can be 10:1 ~ 1:10.This mol ratio can be preferably 3:1 ~ 1:3.
Present invention also offers a kind of pharmaceutical composition, this pharmaceutical composition comprises dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, or comprise according to obtained dabigatran etcxilate glycollate, its hydrate and/or the solvate of method of the present invention, and pharmaceutically acceptable auxiliary material.
Described pharmaceutical composition can comprise dabigatran etcxilate glycollate of the present invention as active substance wherein, can also comprise the material that other has pharmaceutical active simultaneously, to form a kind of pharmaceutical composition of compound for combination therapy.
When dabigatran etcxilate glycollate of the present invention is used for the treatment of as activeconstituents, generally directly not giving patient simple chemical, is all occur with the form of the pharmaceutical composition containing pharmaceutically acceptable auxiliary material usually.Dabigatran etcxilate glycollate of the present invention also can by the administration of any appropriate, usually can be oral or parenteral route, so, the pharmaceutically acceptable auxiliary material that those skilled in the art also can select pharmaceutical composition to comprise according to required form of medication.
Be to be understood that, according to method well known in the art, pharmaceutically acceptable auxiliary material can be the matrix or the auxiliary material that keep pharmaceutical dosage form, usually select according to different medicaments or combinationally use, optionally comprise vehicle, such as, in Microcrystalline Cellulose, lactose, pregelatinized Starch, starch, dextrin, calcium phosphate, sucrose, dextran, N.F,USP MANNITOL, sorbyl alcohol, glucose, fructose, water, polyoxyethylene glycol, propylene glycol, glycerine, cyclodextrin, cyclodextrin derivative one or more etc.; Can also tackiness agent be comprised, such as, in polyvidone (polyvinylpyrrolidone), methylcellulose gum, Walocel MT 20.000PV, HPMC, hydroxypropylcellulose, Natvosol, gelatin, guar gum, xanthan gum one or more etc.; Also comprise lubricant, such as, in Magnesium Stearate, stearic acid, talcum powder, stearyl fumarate, Sodium Lauryl Sulphate BP/USP one or more etc.; Disintegrating agent can also be comprised, such as, in sodium starch glycolate, low-substituted hydroxypropyl cellulose, Xylo-Mucine, cross-linked polyvinylpyrrolidone, croscarmellose sodium, crosslinked carboxymethyl fecula sodium, pregelatinized Starch one or more, etc.; Also comprise tensio-active agent, such as sodium lauryl sulphate, Tween-80 one or more, etc.; PH value regulator or buffer reagent can also be comprised, such as phosphate buffered saline buffer, citric acid, Trisodium Citrate, acetate buffer, dilute hydrochloric acid, sodium carbonate, sodium hydroxide one or more, etc.; Can also sanitas be comprised, such as, in Sodium Benzoate, potassium sorbate, methyl p-hydroxybenzoate, propylparaben one or more, etc.; Stablizer and oxidation inhibitor can also be comprised, such as, in Calcium Disodium Edetate, S-WAT, vitamins C one or more, etc.; Taste conditioning agent can also be comprised, such as, in maltose alcohol, fructose, sucrose, soluble saccharin, orange essence, strawberry flavour one or more, etc.; That can also comprise other routines in addition, appropriate additive.
In addition, when pharmaceutical dosage form be tablet or capsule time, pharmaceutically acceptable auxiliary material can also comprise film dressing.For the material of film dressing, comprise applicable Drug coating, such as HPMC, Natvosol, hydroxypropylcellulose, hydroxypropyl methylcellulose phthalate, etc.; Can also softening agent be comprised, such as polyoxyethylene glycol, triethyl citrate, etc.; Also comprise appropriate solubilizers, as Tween-80; Suitable pigment can also be comprised, as titanium dioxide, various ferric oxide, pink pigment, etc.
According to pharmaceutical composition of the present invention, described pharmaceutical composition can be tablet, hard capsule, soft capsule, pill, granule, pellet or oral fluid agent.
Pharmaceutical composition of the present invention can be prepared as acceptable any pharmaceutical dosage form in pharmaceutics as required, as oral preparations, injection formulations, parenteral liquid preparation, etc.; As oral tablet, capsule, granule, oral solution, powder agent, pill, sublingual administration agent, etc.; And for example injection, comprises powder ampoule agent for injection and injection liquid, etc., the emulsion of eye drop parenteral for another example, nasal drops, [Dan, Transdermal absorption, etc.Also can be the formulation such as quick-release, slowly-releasing, controlled release of above various formulation, such as oral dispersible tablet, slow releasing tablet, chewable tablet, slow releasing capsule, enteric coated tablet, effervescent tablet, orally disintegrating tablet, Special-shaped sheet, effervescent granule, etc.Especially, prepare by means known in the art, be preferred for preparing tablet (comprising dispersible tablet, slow releasing tablet, chewable tablet, enteric coated tablet, orally disintegrating tablet, Special-shaped sheet) edible in pharmaceutics, capsule (comprise stomach is molten, enteric, slow releasing capsule), granule, oral solution, injection (comprising powder ampoule agent for injection and injection liquid) etc., to meet the various needs on Clinical practice.
According to pharmaceutical composition of the present invention, wherein, in described pharmaceutical composition, the weight ratio of described dabigatran etcxilate glycollate and described pharmaceutically acceptable auxiliary material can be 1:1 ~ 5, can be preferably 1:1 ~ 2.The content of dabigatran etcxilate glycollate in pharmaceutical composition can be 0.1 ~ 100mg, can be such as 0.1mg, 0.5mg, 1mg, 1.1mg, 1.2mg, 1.3mg, 1.4mg, 1.5mg, 1.6mg, 1.7mg, 1.8mg, 1.9mg, 2mg, 2.5mg, 3mg, 3.5mg, 4mg, 4.5mg, 5mg, 6mg, 7mg, 8mg, 9mg, 10mg, 15mg, 20mg, 25mg, 30mg, 35mg, 40mg, 45mg, 50mg, 60mg, 70mg, 80mg, 90mg, 100mg, 110mg, 120mg, 130mg, 140mg or 150mg, etc.
Present invention also offers dabigatran etcxilate glycollate of the present invention, its hydrate and/or solvate, or according to dabigatran etcxilate glycollate, its hydrate and/or solvate that method of the present invention obtains, the application in the medicine for the preparation for the treatment of or preventing cardiovascular disease.Can preferably for the preparation for the treatment of or prevention phlebothrombosis or acute coronary syndrome medicine in application.
Dabigatran etcxilate glycollate provided by the present invention, its hydrate and/or solvate have higher liberation degree, and its water-soluble acquisition is greatly improved.This can make dissolution process more rapid on the one hand, also can reduce the amount of required aqueous solvent on the other hand.In addition, dabigatran etcxilate glycollate of the present invention and hydrate thereof and solvate also have higher stability and bioavailability.
Be prepared as pharmaceutically active substances or preparation, storage and application galenical time, the improvement of above biochemical property is very important, this can ensure that the quality of galenical is higher, and its high stability also makes the procedure of processing of post-processed more simple, reduces production cost.Further, its high crystalline can use the releases of analytical procedure to its hydrate or solvate such as such as X-ray diffraction to carry out simple and clear analysis, to carry out appropriate selection.These factors for active substance quality and for preparation, store and administration time galenical for, be all very important.In addition, because the activeconstituents in galenical is more stable, complicated preparation work can thus be avoided.
Use physical-chemical operates, and as galenic process such as dry, screening, grinding and medicament figurations, comprises combination treatment, granulation, spray-drying, compressing tablet etc., active substance can be made to absorb or loss moisture.This is also subject to the impact of temperature in environment residing for it and relative humidity.When preparing some preparations, free-water can be introduced into Bound moisture or in handled material, add water because of the relating operation of preparation process together with vehicle.Therefore, under differing temps and relative humidity, pharmaceutically active substances can contact within quite long period with free-water.In the case, dabigatran etcxilate glycollate of the present invention does not show measurable moisture absorption or loss, therefore this stability is conducive to the final stage of its chemical preparation, also the treatment stage of being conducive to the galenic of different dosage form, and its stable lasting validity is of value to patient equally.
Meanwhile, dabigatran etcxilate glycollate of the present invention also has better solvability or compressibility, is thus more suitable for directly being compressed into corresponding tablet formulation or capsule.
In addition, dabigatran etcxilate glycollate of the present invention also has better chemical stability, owing to containing aliphatic amide structure in dabigatran ester molecular structure, easily oxidized, can increase the stability of dabigatran etcxilate after salify.This salt also may have avoiding or reduce the advantage of other active ingredient degradation.
With Compound Phase ratio well known in the prior art, the advantage that described salt also has more effectively, toxicity is lower, action time is longer, field of activity is wider, effect is higher, side effect less, more easily absorbs or other useful pharmacological property.
More specifically, dabigatran etcxilate glycollate of the present invention and hydrate thereof and/or solvate also have but are not limited to following beneficial effect:
1) relative to dabigatran etcxilate mesylate, dabigatran etcxilate glycollate provided by the present invention has satisfactory stability.Such as, dabigatran etcxilate mesylate was degraded to about 50% at 10 days under super-humid conditions, and dabigatran etcxilate glycollate is almost without content.
2) dabigatran etcxilate glycollate of the present invention has water-soluble preferably, confirms through test, and its solubleness in water can reach 2.6mg/mlH
2o (temperature 25 DEG C), and dabigatran etcxilate is almost insoluble when pH value is greater than 4, dabigatran etcxilate mesylate is 1.8mg/ml.Thus dabigatran etcxilate glycollate of the present invention has better compared with dabigatran etcxilate mesylate or at least suitable bioavailability.
3) the dabigatran etcxilate glycollate of the application has lower toxicity, confirm through test, the dabigatran etcxilate glycollate of the application all embodies lower toxicity in acute toxicity test and long term toxicity test, maximal non-toxic dosage can reach 160mg/kg, therefore, there is better security in clinical application.
4) the dabigatran etcxilate glycollate of the application also has good mobility and compressibility.Contriver carries out mobility to dabigatran etcxilate glycollate of the present invention and dabigatran etcxilate mesylate respectively and compressibility measures, and it the results are shown in following table 1.
Table 1 dabigatran etcxilate glycollate and dabigatran etcxilate mesylate etc.
Mobility and compressibility measure
Wherein, the mobility of powder is generally main to be weighed with slope of repose, and slope of repose is less, and mobility is better.Conventional θ≤30 ° good fluidity, θ≤40 ° can meet need of production.Loose density refers to that powder quality is divided by volume of a container shared by this powder, the density of trying to achieve.Its volume used comprises the cumulative volume in space between the hole of particle itself and particle.What loose density was large is heavy, and what loose density was little is lightweight, and the pressure that the large use of loose density is less just can be shaping, shows that compressibility is good.Gu density to knock after vibrations powder quality divided by volume of a container shared by this powder, the density of trying to achieve through certain speed and time.Gu density value shows good fluidity greatly.The less compressibility of compression ratio is better, and being generally less than 0.2 can meet need of production.Above data show, dabigatran etcxilate glycollate of the present invention all shows better mobility and compressibility relative to dabigatran etcxilate mesylate on indices, is thus more suitable for the scale operation of medicine.
Embodiment
Further illustrate the present invention below by specific embodiment, but should be understood to, these embodiments are only used for the use specifically described more in detail, and should not be construed as limiting the present invention in any form.
General description is carried out to the material used in the present invention's test and test method in this part.Although for realizing many materials that the object of the invention uses and working method is well known in the art, the present invention still describes in detail as far as possible at this.It will be apparent to those skilled in the art that within a context, if not specified, material therefor of the present invention and working method are well known in the art.
If no special instructions, the mass spectrograph used in following examples is Agientl100 type level Four bar LC-MS instrument, and the nuclear magnetic resonance analyser used is BrukerARX-400NMR type nuclear magnetic resonance analyser.
embodiment 1
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 1.6mmol and the oxyacetic acid of 1.6mmol are joined in the dehydrated alcohol of 25ml at 20 DEG C, mix and blend 6 hours salifies, then crystallization at 20 DEG C, filter, use ethyl acetate is washed, after drying, the alcohol solvent compound of the dabigatran etcxilate glycollate of 0.387g is obtained.Record ESI-MS (electron spray ionisation-mass spectrum) (m/z): 750 [M+H]
+.
Carry out drying to above-mentioned alcohol solvent compound, obtain the dabigatran etcxilate glycollate 0.363g of white solid, as calculated, in above-mentioned alcohol solvent compound, the content of dabigatran etcxilate glycollate is 93.9wt%.Ethanol containing 0.5 molecule in this ether solvent compound of per molecule.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):704[M+H]
+
1HNMR(400MHz,DMSO-d6)δ:0.87(t,J＝9.0Hz,3H,CH
3),1.08(t,J＝8.4Hz,3H,CH
3),1.27-1.34(dd,6H,CH
2CH
2CH
2),1.56-1.62(m,2H，CH
2),2.64-2.67(m,2H，CH
2),3.74(s,3H,CH
3),3.92-4.01(m,4H，2CH
2),4.23(t,J＝14.4Hz,2H,CH
2),4.46(S,2H,CH
2)4.56(d,J＝5.6Hz,2H,CH
2),6.77(d,J＝8.8Hz,2H,ArH),6.93(d,J＝7.6Hz,1H,ArH),7.11-7.13(m,1H,ArH),7.19-7.22(m,2H,ArH),7.30-7.33(m,1H,ArH),7.37-7.42(m,1H,ArH),7.47-7.54(m,1H,ArH),7.78-7.80(m,2H,ArH),8.33(d,J＝4.0Hz,1H,ArH),9.24(m,2Hbr,2H,NH
2).
Fusing point: 147-149 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C61.48N13.92H6.44O18.18
Calculate: n=1
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
embodiment 2
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 3.2mmol and the oxyacetic acid of 1.6mmol are joined in 20ml water at 30 DEG C, mix and blend 6 hours salifies, then crystallization at 30 DEG C, filter, use ethyl acetate is washed, after drying, add water and carry out recrystallization, obtain the hydrate of the dabigatran etcxilate glycollate of 0.429g.Record ESI-MS (m/z): 684 [M+H]
+.
Carry out drying to above-mentioned hydrate, obtain the dabigatran etcxilate glycollate 0.417g of white solid, as calculated, in above-mentioned hydrate, the content of dabigatran etcxilate glycollate is 97.4wt%.Water containing 1 molecule in this hydrate of per molecule, i.e. monohydrate.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):666[M+H]
+
1HNMR(400MHz,DMSO-d6)δ:0.85(t,J＝9.0Hz,3H,CH
3),1.09(t,J＝8.4Hz,3H,CH
3),1.28-1.35(dd,6H,CH
2CH
2CH
2),1.57-1.64(m,2H，CH
2),2.63-2.65(m,2H，CH
2),3.75(s,3H,CH
3),3.92-4.01(m,4H，2CH
2),4.23(t,J＝14.4Hz,2H,CH
2),4.46(S,1H,CH
2)4.56(d,J＝5.6Hz,2H,CH
2),6.77(d,J＝8.8Hz,2H,ArH),6.95(d,J＝7.6Hz,1H,ArH),7.12-7.14(m,1H,ArH),7.18-7.21(m,2H,ArH),7.31-7.34(m,1H,ArH),7.38-7.42(m,1H,ArH),7.47-7.55(m,1H,ArH),7.77-7.80(m,2H,ArH),8.35(d,J＝4.0Hz,1H,ArH),9.25(m,2Hbr,2H,NH
2).
Fusing point: 139-141 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C63.16N14.72H6.50O15.62
Calculate: n=2
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
embodiment 3
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 4.8mmol and the oxyacetic acid of 1.6mmol are joined in 20ml dehydrated alcohol at 0 DEG C, mix and blend 6 hours salifies, then crystallization at 0 DEG C, filter, use ethyl acetate is washed, after drying, add glycol dimethyl ether and carry out recrystallization, obtain the dabigatran etcxilate glycollate 0.417g of white solid.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):654[M+H]
+
1HNMR(400MHz,DMSO-d6)δ:0.86(t,J＝9.0Hz,3H,CH
3),1.08(t,J＝8.4Hz,3H,CH
3),1.27-1.34(dd,6H,CH
2CH
2CH
2),1.56-1.63(m,2H，CH
2),2.64-2.66(m,2H，CH
2),3.75(s,3H,CH
3),3.93-4.01(m,4H，2CH
2),4.24(t,J＝14.4Hz,2H,CH
2),4.47(S,2/3H,CH
2)4.57(d,J＝5.6Hz,2H,CH
2),6.76(d,J＝8.8Hz,2H,ArH),6.95(d,J＝7.6Hz,1H,ArH),7.11-7.14(m,1H,ArH),7.18-7.22(m,2H,ArH),7.30-7.34(m,1H,ArH),7.39-7.42(m,1H,ArH),7.47-7.56(m,1H,ArH),7.76-7.80(m,2H,ArH),8.34(d,J＝4.0Hz,1H,ArH),9.23(m,2Hbr,2H,NH
2).
Fusing point: 131-133 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C63.78N15.00H6.53O14.69
Calculate: n=3
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
embodiment 4
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 1.6mmol and the oxyacetic acid of 4.8mmol are joined in 20ml anhydrous methanol at 30 DEG C, mix and blend 6 hours salifies, then crystallization at 10 DEG C, filter, use washed with diethylether, after drying, add tetrahydrofuran (THF) and carry out recrystallization, obtain the tetrahydrofuran solvate of the dabigatran etcxilate glycollate of 0.320g.Record its ESI-MS (m/z): 752 [M+H]
+.
Carry out drying to above-mentioned tetrahydrofuran solvate, obtain the dabigatran etcxilate glycollate 0.304g of white solid, as calculated, in above-mentioned solvate, the content of dabigatran etcxilate glycollate is 95.1wt%.Tetrahydrofuran (THF) containing 0.5 molecule in this tetrahydrofuran solvate of per molecule.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):704[M+H]
+。
Fusing point: 147-149 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C61.48N13.92H6.44O18.18
Calculate: n=1
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
embodiment 5
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 1.6mmol and the oxyacetic acid of 3.2mmol are joined 20ml acetone at 10 DEG C, mix and blend 6 hours salifies, then crystallization at 10 DEG C, filter, use washed with diethylether, after drying, add acetone and carry out recrystallization, obtain the acetone solvate of the dabigatran etcxilate glycollate of 0.419g.Record its ESI-MS (m/z): 733 [M+H]
+.
Carry out drying to above-mentioned acetone solvate, obtain the dabigatran etcxilate glycollate 0.402g of white solid, as calculated, in above-mentioned solvate, the content of dabigatran etcxilate glycollate is 96.0wt%.Acetone containing 0.5 molecule in this acetone solvate of per molecule.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):704[M+H]
+。
Fusing point: 147-149 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C61.48N13.92H6.44O18.18
Calculate: n=1
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
embodiment 6
The present embodiment is for illustration of the preparation of dabigatran etcxilate glycollate of the present invention.
The dabigatran etcxilate of 1.6mmol and the oxyacetic acid of 8mmol are joined in 20ml trichloromethane at 30 DEG C, mix and blend 6 hours salifies, then crystallization at 20 DEG C, filter, use washed with diethylether, after drying, add water and carry out recrystallization, obtain the hydrate of the dabigatran etcxilate glycollate of 0.400g.Record its ESI-MS (m/z): 713 [M+H]
+.
Carry out drying to above-mentioned hydrate, obtain the dabigatran etcxilate glycollate 0.395g of white solid, as calculated, in above-mentioned hydrate, the content of dabigatran etcxilate glycollate is 98.7wt%.Water containing 0.5 molecule in this hydrate of per molecule, i.e. semihydrate.
Above-mentioned dabigatran etcxilate glycollate is measured:
ESI-MS(m/z):704[M+H]
+。
Fusing point: 147-149 DEG C
Ultimate analysis:
C
34H
41N
7O
5(627.74)·1/nC
2H
4O
3
Discovery value: C61.48N13.92H6.44O18.18
Calculate: n=1
The molecular structural formula of therefore obtained dabigatran etcxilate glycollate is:
Stability test:
Contriver observes the dabigatran etcxilate glycollate of embodiment 1 and dabigatran etcxilate mesylate and makes assay under differing temps, humidity and illumination condition, and data are in table 2 and table 3.
Liquid-phase condition:
Chromatographic column: AgelaVenusilMPC18 post (4.6mm × 250mm, 5 μm) NO:VA952505-0
Moving phase: 0.01molL
-1secondary ammonium phosphate damping fluid-methyl alcohol (40:60);
Flow velocity: 1mlmin
-1; Determined wavelength: 250nm; Column temperature: 25 DEG C; Sample size: 20 μ l
The content of table 2 dabigatran etcxilate glycollate and dabigatran etcxilate mesylate etc.
Table 2 is the contrast of content through influence factor test-results of dabigatran etcxilate glycollate and mesylate.Data show, under the same conditions (high temperature, high humidity, illumination), and the former content changes very little in time, belong to error at measurment scope, and the latter is very unstable under conditions of high humidity, especially can be degraded to about 50% at 10 days under super-humid conditions, shows obvious unstable.
The appearance change of table 3 dabigatran etcxilate glycollate and dabigatran etcxilate mesylate
As known from Table 3, under hot conditions, dabigatran etcxilate glycollate is almost unchanged, and dabigatran etcxilate mesylate can be observed color and produces considerable change in time.Under super-humid conditions, the former outward appearance is almost constant, shows more stable character, and the latter then moisture absorption is serious.
embodiment 7
The present embodiment is for illustration of the contrast of the blood coagulation resisting function of dabigatran etcxilate mesylate and dabigatran etcxilate glycollate.
To 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-glycollate (embodiment 1 prepares) and 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate blood coagulation resisting function comparative study.Test method is as follows:
Get the Kunming mouse that body weight is (20 ± 2) g health, be divided into 3 groups at random, often organize 10, male and female half and half, administering mode is:
Blank group---to equal-volume physiological saline
Control group---administration mesylate (1.186mg/kg presses active substance and calculates)
Treatment group---administration glycollate (1.186mg/kg presses active substance and calculates)
Feeding after 2 days in the lab and test, is that cutting off apart from Mouse Tail-tip 3cm place, blood flows out naturally with etherization after 0.25mL24h to the gavage volume of mouse.Dip in blood with filter paper gently at Mouse Tail-tip, once, till wire drawing phenomenon appears in blood, at this moment blood has setting condition to per minute, each test all with same wire drawing phenomenon for benchmark, writing time.Record result as shown in table 4.
Table 4 anticoagulation time (mean ± standard deviation, n=10)
Above data show, 3-shown in the embodiment of the present invention 1 [(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino] the anticoagulation comparative evaluation data of-ethyl propionate-glycollate are better than 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate, there is statistical significance.
embodiment 8
The present embodiment is for illustration of the pharmacokinetics comparing result of dabigatran etcxilate mesylate and dabigatran etcxilate glycollate.
To 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-glycollate (embodiment 1 prepares) and 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate pharmacokinetics comparative study.Test method is as follows:
Get the SD rat that body weight is (200 ± 20) g health, be divided into 3 groups at random, often organize 10, male and female half and half, administering mode is:
Control group---administration mesylate (0.945mg/kg presses active substance and calculates, and this dosage is lower same according to the middle man and animal body surface area ratio dose ratio meter of professor Xu Shuyun chief editor " pharmacological experimental methodology ");
Treatment group---administration glycollate (0.945mg/kg presses active substance and calculates).
Gastric infusion, after administration respectively at 10,15,25,35,45,60,120,180,240,360min tail venous blood sampling, be positioned in 4 DEG C of refrigerators and store, sample passes through organic solvent extraction, vacuum-drying, after be dissolved in redistilled water, carry out HPLC analysis.Record result as shown in table 5.
The pharmacokinetics of table 5 dabigatran etcxilate mesylate and dabigatran etcxilate glycollate contrasts
| C max(ng/ml) | AUC 0-(ng·h/ml) | T Max(h) | T 1/2(h) | |
| Control group (mesylate group) | 74.1 | 683 | 1.5 | 13.2 |
| Treatment group (glycollate group) | 74.6 | 690 | 1.5 | 13.4 |
Table 5 result shows: 3-shown in the embodiment of the present invention 1 [(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-glycollate and 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate medicine is in vivo similar for parameter value, there was no significant difference (P>0.05).
embodiment 9
The present embodiment is for illustration of the acute toxicity comparing result of dabigatran etcxilate mesylate and dabigatran etcxilate glycollate.
To 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-glycollate (embodiment 1 prepares) and 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate acute toxicity comparative study.Test method is as follows:
Adopt 2000mg.kg
-1as being fixed to pharmaceutical quantities, CD-1 mouse, 10, male and female half and half, dabigatran etcxilate mesylate administration group and dabigatran etcxilate glycollate administration group press 2000mg.kg
-1dosage, with 0.5%CMCNa (Xylo-Mucine) for blank Vehicle controls group.Observe the toxic reaction in 14 days after the survival rate of animal and administration every day.Respectively the 1st, 8, the body weight (before administration, mean body weight is 20.2 ± 1.67g) of 15 day entries every animal.All animals are before dying or put to death for 15th, and carry out ptomatopsia.Main result is as shown in table 6:
Table 6 acute toxicity test comparing result
Compared with Vehicle controls group, mesylate administration group animal within the observation period occurs that autonomic activities reduces, prostrate, breathe with difficulty, the non-specific toxicity reaction such as eyelid diminishes, perpendicular hair, the visible digestive tube of autopsy findings of animal, Tiroidina, and pancreatic hemorrhage, animal dead may be relevant to hemorrhage.In the 14 day observation period of glycollate group after the administration same day and administration, animal movement situation, eyelid indication, breathing, fur, movement and secretory product etc. are showed no obvious abnormalities.Observation period terminates, and animal cuts open inspection substantially, and the head of animal, body surface, subcutaneous and neck inspection are showed no obvious abnormalities, and all internal organs have no obvious bleeding, animal dysoemia.
Above data show, 3-shown in the embodiment of the present invention 1 [(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino] the acute toxicity comparative evaluation data of-ethyl propionate-glycollate are obviously better than 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate.
embodiment 10
The present embodiment is for illustration of the long term toxicity comparing result repeating gastric infusion for 3 months of dabigatran etcxilate mesylate and dabigatran etcxilate glycollate.
To 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-glycollate (embodiment 1 prepares) and 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate 3 months long term toxicity comparative study.Observe the toxic action repeating gastric infusion and rat is produced for continuous 3 months, judge the character of toxicity, degree, dose-response relationship and reversibility, predict possible toxicity target organ or target tissue.
Test method is as follows:
Dabigatran etcxilate mesylate and dabigatran etcxilate glycollate of the present invention respectively by 0,10,40, the dosage of 160mg/kg arranges administration group and oral administration, with 0.5%CMCNa for blank Vehicle controls group.Each administration group has rat 24, male and female half and half; Each administration group rat is through gastric infusion, and Per-Hop behavior 6 days, daily 1 time, observes the abnormal response after animals administer every day, carries out weekly 1 body weight and food-intake inspection, before administration 5 weeks, increases weekly a measured body weight mid-term; Recover after 30 days after administration 3 months and medicine, the often laboratory animal of group difference Stochastic choice 1/2, male and female half and half, carry out blood, biochemistry, ionogen, blood coagulation, substantially cut open inspection, organ weights, histopathological examination, each group of detected result compares with solvent control group respectively, and comprehensive trial-product of analyzing is on the impact of the every Index for examination of rat.
Main result: 1. during administration dabigatran etcxilate mesylate high dose group mortality ratio (5/24) higher than dabigatran etcxilate glycollate group (1/24); 2. dabigatran etcxilate mesylate high dose group rat body weight all obviously reduces (p<0.05, table 7) compared with dabigatran etcxilate glycollate group with food-intake; 3. dabigatran etcxilate mesylate high dose group rats'liver transaminase (gpt (ALT) and glutamic-oxal(o)acetic transaminase (AST)) obvious reduction (p<0.05) compared with dabigatran etcxilate glycollate group; 4. respectively coagulation function inspection is organized, compared with dabigatran etcxilate mesylate administration group, the middle and high dosage group extrinsic soagulation PT of dabigatran etcxilate glycollate administration group all obviously extends, PT leads (PTR) and INR (INR) obviously raises, and PT mobility (PT%) obviously reduces; The intrinsic coagulation APTT of the middle and high dosage group of dabigatran etcxilate glycollate administration group obviously extends (table 8), the change of these indexs is caused by drug action, and there is dose-dependently, the change drug withdrawal of coagulation function simultaneously can recover normal after 30 days, all can not be delayed toxicity (table 9); 5. organ weights and histopathological examination find, compared with solvent control group, the organ weights such as dabigatran etcxilate mesylate high dosage administration group liver, kidney, thymus gland obviously reduce (table 10); Further, the visible digestive tube of rat of dabigatran etcxilate mesylate high dosage administration group, Tiroidina and pancreatic hemorrhage, the maximal non-toxic dosage (NOAEL) of dabigatran etcxilate mesylate is 40mg/kg; And dabigatran etcxilate glycollate there is no above bleeding risk, maximal non-toxic dosage (NOAEL) is 160mg/kg.
Table 7 respectively before group gastric infusion 5 weeks rat body weights change (
g)
Note: n represents animal number of elements, and t inspection between employing group, * compares P<0.05 with solvent control group
The table 8 respectively group gastric infusion impact on rat coagulation function in 90 days (
)
Note: n represents animal number of elements, and between employing group, t inspection, compares with same dosage mesylate group, * P < 0.05, * * P < 0.01
Table 9 respectively group drug withdrawal recover the impact on rat coagulation function in 30 days (
)
Note: n represents animal number of elements
The table 10 respectively group gastric infusion impact on Rats Organs and Tissues weight in 90 days (
g)
Note: n represents animal number of elements, and between employing group, t inspection, compares * P < 0.05 with solvent control group
More than research shows, 3-shown in the embodiment of the present invention 1 [(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino] the long term toxicity comparative evaluation data of 3 months repeat administrations of-ethyl propionate-glycollate are better than 3-[(2-{4-(hexyloxy carbonyl amino-imino-methyl)-phenylamino]-methyl }-1-methyl isophthalic acid H benzoglyoxaline-5-carbonyl)-pyridine-2-base-amino]-ethyl propionate-mesylate, bleeding risk obviously reduces.
embodiment 11
The present embodiment is for illustration of the preparation of the pharmaceutical composition of dabigatran etcxilate glycollate of the present invention.
Dabigatran etcxilate glycollate is crossed 80 mesh sieves, and 60 mesh sieves crossed by auxiliary material.Take dabigatran etcxilate oxyacetic acid, Microcrystalline Cellulose and lactose by recipe quantity fully to mix, add 1% (weight/volume) hypromellose aqueous solution, softwood processed, sieves, wet granular processed, in 55 DEG C of dryings.Polyvinylpolypyrrolidone and Magnesium Stearate are added in above-mentioned particle, measure intermediates content, compressing tablet, packaging.
embodiment 12
The present embodiment is for illustration of the preparation of the pharmaceutical composition of dabigatran etcxilate glycollate of the present invention.
Dabigatran etcxilate glycollate is crossed 80 mesh sieves, and 60 mesh sieves crossed by auxiliary material.Take dabigatran etcxilate oxyacetic acid, Microcrystalline Cellulose, pregelatinized Starch and lactose by recipe quantity fully to mix, add 1% (weight/volume) hypromellose aqueous solution, softwood processed, sieves, wet granular processed, in 55 DEG C of dryings.Magnesium Stearate is added in above-mentioned particle, measures intermediates content, encapsulated, packaging.
embodiment 13
The present embodiment is for illustration of the preparation of the pharmaceutical composition of dabigatran etcxilate glycollate of the present invention.
Dabigatran etcxilate glycollate is crossed 80 mesh sieves, and 60 mesh sieves crossed by auxiliary material.Take dabigatran etcxilate glycollate by recipe quantity, lactose, N.F,USP MANNITOL, aspartame, essence fully mixes, add 2% (weight/volume) hypromellose aqueous solution softwood again, 16 mesh sieves are granulated, 55 DEG C of dryings, the whole grain of 14 mesh sieve, measure intermediates content and moisture, packaging, altogether obtained 100 bags of granules.
embodiment 14
The present embodiment is for illustration of the preparation of the pharmaceutical composition of dabigatran etcxilate glycollate of the present invention.
Dabigatran etcxilate glycollate is crossed 80 mesh sieves, and 60 mesh sieves crossed by auxiliary material.Take dabigatran etcxilate oxyacetic acid, polyvidone, aspartame and essence by recipe quantity first to mix, more fully mix with N.F,USP MANNITOL, Microcrystalline Cellulose and lactose successively, finally add Magnesium Stearate and mix, measure intermediates content, compressing tablet, packaging.
Although present invention has been description to a certain degree, significantly, under the condition not departing from the spirit and scope of the present invention, can carry out the suitable change of each condition.Be appreciated that and the invention is not restricted to described embodiment, and be attributed to the scope of claim, it comprises the equivalent replacement of described each factor.
Claims (10)
1. there is the dabigatran etcxilate glycollate of general formula (I) structure, its hydrate and/or a solvate,
Wherein, n is 1,2 or 3.
2. dabigatran etcxilate glycollate according to claim 1, its hydrate and/or solvate, is characterized in that, the water containing 0.5 ~ 10 molecule in the hydrate of dabigatran etcxilate glycollate described in per molecule, is preferably the water containing 0.5 ~ 2 molecule; Solvent containing 0.5 ~ 10 molecule in the solvate of dabigatran etcxilate glycollate described in per molecule, is preferably the solvent containing 0.5 ~ 2 molecule.
3. dabigatran etcxilate glycollate according to claim 1 and 2, its hydrate and/or solvate, it is characterized in that, described solvate is one or more in alcohol solvent compound, Methanol Solvate, acetone solvate, acetonitrile solvate, ethyl acetate solvate, tetrahydrofuran solvate and ether solvent compound.
4. dabigatran etcxilate glycollate according to any one of claim 1 to 3, its hydrate and/or solvate, it is characterized in that, in described hydrate, dabigatran etcxilate glycollate accounts for more than 95wt%, be preferably more than 98wt%, be more preferably more than 99wt%; In described solvate, dabigatran etcxilate glycollate accounts for more than 95wt%, is preferably more than 98wt%, is more preferably more than 99wt%.
5. the preparation method of dabigatran etcxilate glycollate according to any one of claim 1 to 4, its hydrate and/or solvate, it is characterized in that, the method comprises: dabigatran etcxilate and oxyacetic acid are mixed salify and crystallization in water or the first organic solvent, after filtration, after washing, drying, water or the second organic solvent is used to carry out recrystallization, obtained described dabigatran etcxilate glycollate, its hydrate or solvate.
6. preparation method according to claim 5, it is characterized in that, described mixing salify carries out under 0 DEG C of reflux temperature to water or the first organic solvent, described first organic solvent and the second organic solvent identical or different, be selected from ethanol, methyl alcohol, propyl alcohol, Virahol, butanols, ethyl formate, ethyl acetate, isopropyl acetate, butylacetate, ether, isopropyl ether, n-butyl ether, glycol dimethyl ether, methyl tert-butyl ether, tetrahydrofuran (THF), sherwood oil, acetonitrile, methylene dichloride, trichloromethane, normal hexane, hexanaphthene, acetone, butanone, pentanone, toluene, one or more in N,N-DIMETHYLACETAMIDE or dimethylbenzene.
7. the preparation method according to claim 5 or 6, is characterized in that, the mol ratio of described dabigatran etcxilate and described oxyacetic acid is 10:1 ~ 1:10, is preferably 3:1 ~ 1:3.
8. a pharmaceutical composition, it is characterized in that, this pharmaceutical composition comprises dabigatran etcxilate glycollate, its hydrate and/or solvate according to any one of Claims 1-4, or according to dabigatran etcxilate glycollate, its hydrate and/or solvate that the method according to any one of claim 5 to 7 obtains, and pharmaceutically acceptable auxiliary material;
Preferably, in described pharmaceutical composition, the weight ratio of described dabigatran etcxilate glycollate and described pharmaceutically acceptable auxiliary material is 1:1 ~ 5, is more preferably 1:1 ~ 2.
9. pharmaceutical composition according to claim 8, is characterized in that, described pharmaceutical composition is tablet, hard capsule, soft capsule, pill, granule, pellet or oral fluid agent.
10. the dabigatran etcxilate glycollate according to any one of Claims 1-4, its hydrate and/or solvate, or according to dabigatran etcxilate glycollate, its hydrate and/or the solvate application in the medicine for the preparation for the treatment of or preventing cardiovascular disease that the method according to any one of claim 5 to 7 obtains, be preferably the application in the medicine for the preparation for the treatment of or prevention phlebothrombosis or acute coronary syndrome.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410408463.1A CN105367551A (en) | 2014-08-19 | 2014-08-19 | Dabigatran etexilate glycolate, preparation method and applications thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201410408463.1A CN105367551A (en) | 2014-08-19 | 2014-08-19 | Dabigatran etexilate glycolate, preparation method and applications thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105367551A true CN105367551A (en) | 2016-03-02 |
Family
ID=55370238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201410408463.1A Pending CN105367551A (en) | 2014-08-19 | 2014-08-19 | Dabigatran etexilate glycolate, preparation method and applications thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105367551A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105348260A (en) * | 2014-08-19 | 2016-02-24 | 天津药物研究院 | Dabigatran etexilate hydrobromide, preparation method and applications thereof |
| CN105348259A (en) * | 2014-08-19 | 2016-02-24 | 天津药物研究院 | Dabigatran etexilate oxaloacetate, preparation method and applications thereof |
| CN106565546A (en) * | 2016-10-21 | 2017-04-19 | 武汉桀升生物科技有限公司 | Lauroyl arginine ethyl ester glycol acid salt and preparation method and application thereof |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| CN102633777A (en) * | 2012-03-31 | 2012-08-15 | 天津药物研究院 | Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof |
| CN103127109A (en) * | 2013-02-05 | 2013-06-05 | 南京华威医药科技开发有限公司 | Pharmaceutical composition containing dabigatran etexilate or salt and hydrate thereof |
| CN103304539A (en) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | Dabigatran etexilate malate, and preparation method and application thereof |
| CN103570679A (en) * | 2012-07-19 | 2014-02-12 | 天津拓飞生物科技有限公司 | Dabigatran etexilate gluconate, preparation method and application thereof |
-
2014
- 2014-08-19 CN CN201410408463.1A patent/CN105367551A/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20100087488A1 (en) * | 2006-10-10 | 2010-04-08 | Boehringer Ingelheim International Gmgh | Physiologically Acceptable Salts of 3-[(2--1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester |
| WO2012077136A2 (en) * | 2010-12-06 | 2012-06-14 | Msn Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
| CN103304539A (en) * | 2012-03-07 | 2013-09-18 | 天津药物研究院 | Dabigatran etexilate malate, and preparation method and application thereof |
| CN102633777A (en) * | 2012-03-31 | 2012-08-15 | 天津药物研究院 | Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof |
| CN103570679A (en) * | 2012-07-19 | 2014-02-12 | 天津拓飞生物科技有限公司 | Dabigatran etexilate gluconate, preparation method and application thereof |
| CN103127109A (en) * | 2013-02-05 | 2013-06-05 | 南京华威医药科技开发有限公司 | Pharmaceutical composition containing dabigatran etexilate or salt and hydrate thereof |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105348260A (en) * | 2014-08-19 | 2016-02-24 | 天津药物研究院 | Dabigatran etexilate hydrobromide, preparation method and applications thereof |
| CN105348259A (en) * | 2014-08-19 | 2016-02-24 | 天津药物研究院 | Dabigatran etexilate oxaloacetate, preparation method and applications thereof |
| CN106565546A (en) * | 2016-10-21 | 2017-04-19 | 武汉桀升生物科技有限公司 | Lauroyl arginine ethyl ester glycol acid salt and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102633777B (en) | Dabigatran etexilate 2-ketoglutarate as well as preparation method and application thereof | |
| CN103304539A (en) | Dabigatran etexilate malate, and preparation method and application thereof | |
| US20090324718A1 (en) | Imatinib compositions | |
| BR112015031979B1 (en) | Letermovir, solid oral pharmaceutical formulation, use of a solid oral pharmaceutical formulation, and process for preparing letermovir | |
| EP3658122B1 (en) | Pharmaceutical composition comprising sacubitril and valsartan | |
| EP1902713A1 (en) | Pharmaceutical composition containing thiazolidinedione compound | |
| CN105367551A (en) | Dabigatran etexilate glycolate, preparation method and applications thereof | |
| CN117257807A (en) | Solid dispersion | |
| ES2622568T3 (en) | Tablet containing 5-hydroxy-1H-imidazol-4-carboxamide | |
| CN105440017A (en) | Dabigatran etexilate vanillate and preparation method and application thereof | |
| CN105348261A (en) | Dabigatran etexilate pyruvate, preparation method and applications thereof | |
| CN105348260A (en) | Dabigatran etexilate hydrobromide, preparation method and applications thereof | |
| CN105348259A (en) | Dabigatran etexilate oxaloacetate, preparation method and applications thereof | |
| WO2019230937A1 (en) | Solid oral dosage form having excellent dissolution properties | |
| KR101446129B1 (en) | Process for preparing pranlukast-containing solid formulation | |
| CN103664880A (en) | Novel anticoagulation medicine and preparation method and application thereof | |
| CN103570679A (en) | Dabigatran etexilate gluconate, preparation method and application thereof | |
| EP3601278B1 (en) | Crystalline form of masitinib | |
| CN103304602A (en) | Dabigatran etexilate gluconate, and preparation method and application thereof | |
| CN106176642B (en) | A kind of Disket and preparation method thereof for treating respiratory disease | |
| CN103570680A (en) | Dabigatran etexilate levulinic acid salt, preparation method and application thereof | |
| CN103509004A (en) | Dabigatran caffeic acid salt as well as preparation method and application thereof | |
| AU2014336389B2 (en) | Pharmaceutical dosage forms containing sodium-1-[6-(morpholin-4-yl)pyrimidin-4-yl]-4-(1H-1,2,3-triazol-1-yl)-1H-pyrazol-5-olate | |
| KR102584268B1 (en) | Formulation comprising pirfenidone with improved drug safety and stability and method for the preparing the same | |
| EP3470062A1 (en) | Pharmaceutical tablet composition comprising bilastine and magnesium aluminometasilicate |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160302 |